Asundexian Cuts Risk of Second Stroke - Results from OCEANIC-STROKE скачать в хорошем качестве

Asundexian Cuts Risk of Second Stroke - Results from OCEANIC-STROKE

Asundexian, an investigational oral Factor XIa (FXIa) inhibitor in development by Bayer, has shown its superiority to placebo in preventing ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), based on results from the pivotal phase 3 OCEANIC-STROKE trial. We spoke with Andrew Russman, DO, neurologist and section head of stroke and vascular neurology at the Cleveland Clinic, to learn more. “I think it’s really important to recognize that we’re always concerned that we’re adding bleeding risk. But that was not the case with asundexian in this study. Essentially, patients benefitted by a reduction in their ischemic stroke risk without a concomitant increase in bleeding risk. And this is critically important." Key Timestamps 00:00:01 Intro 00:00:07 Overview of OCEANIC-STROKE 00:03:54 Why FXIa Inhibitors Can Outperform Traditional Anticoagulation 00:05:12 Subgroup analysis of asundexian 00:07:10 FXIa Receptors' Place in the Cascade 00:08:37 Addressing Skepticism About Separating Thrombosis from Hemostasis Read more at https://www.hcplive.com/view/oceanic-... #cardiology #stroke